| Identification | Back Directory | [Name]
Biricodar | [CAS]
159997-94-1 | [Synonyms]
Biricodar
VX-710(biricodar)
2-Piperidinecarboxylic acid, 1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester, (2S)- | [Molecular Formula]
C34H41N3O7 | [MDL Number]
MFCD28138411 | [MOL File]
159997-94-1.mol | [Molecular Weight]
603.71 |
| Chemical Properties | Back Directory | [Boiling point ]
752.1±70.0 °C(Predicted) | [density ]
1.195±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Oil | [pka]
5.80±0.10(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
Biricodar (VX-710) is a modulator of P-glycoprotein and MRP-1; shows effective chemosensitizing activity in multidrug resistant cells. | [Definition]
ChEBI: Biricodar is an alpha-amino acid ester. | [storage]
Store at -20°C | [References]
[1] Minderman H, et al. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res. 2004 Mar 1;10(5):1826-34. DOI:10.1158/1078-0432.ccr-0914-3
[2] Yanagisawa T, et al. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 1999 Jun;80(8):1190-6. DOI:10.1038/sj.bjc.6990485
[3] Germann UA, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997 Feb;8(2):125-40. DOI:10.1097/00001813-199702000-00004 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|